What is NDC 61703-339?

61703-339 is the product NDC for Carboplatin, Carboplatin 10 mg/mL injection, solution, listed with the FDA by Hospira, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.

Hospira, Inc., NDC labeler code 61703. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Carboplatin?

31 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Carboplatin NDC 61703-339 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)61703-339Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61703-0339Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
61703-339-18	6170303391861703033918	1 VIAL, MULTI-DOSE in 1 CARTON (61703-339-18) / 5 mL in 1 VIAL, MULTI-DOSEMarketed from Oct 14, 2004
61703-339-22	6170303392261703033922	1 VIAL, MULTI-DOSE in 1 CARTON (61703-339-22) / 15 mL in 1 VIAL, MULTI-DOSEMarketed from Oct 14, 2004
61703-339-50	6170303395061703033950	1 VIAL, MULTI-DOSE in 1 CARTON (61703-339-50) / 45 mL in 1 VIAL, MULTI-DOSEMarketed from Oct 14, 2004
61703-339-56	6170303395661703033956	1 VIAL, MULTI-DOSE in 1 CARTON (61703-339-56) / 60 mL in 1 VIAL, MULTI-DOSEMarketed from Nov 23, 2004

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carboplatin
Generic name (nonproprietary): carboplatin
Active ingredients: Carboplatin — 10 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Hospira, Inc.NDC labeler code 61703
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076517
Marketing start: Oct 14, 2004
Listing expires: Dec 31, 2026
Other FDA classes: Platinum-containing Compounds (EXT)
Identifiers: Product ID 61703-339_0ddf4411-7138-412a-908a-fadf22bdfb79SPL ID 0ddf4411-7138-412a-908a-fadf22bdfb79SPL set ID c3ae9880-44bb-4f4e-93d8-8a5e21708a30RxCUI 597195UNII BG3F62OND5
Pharmacologic class: Platinum-based Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N461703033918 followed by a unit qualifier and the quantity

Package 61703-0339-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 20, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) becau…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 61703-339

What is NDC 61703-339?: 61703-339 is the product NDC for Carboplatin, Carboplatin 10 mg/mL injection, solution, listed with the FDA by Hospira, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Carboplatin.
What is the active ingredient?: Carboplatin.
Who is the labeler?: Hospira, Inc., NDC labeler code 61703. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Carboplatin?: 31 other product NDCs are listed under this name. See all Carboplatin NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Carboplatin NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Carboplatin	Carboplatin 50 mg/5mL	Injection, SolutionIntravenous	Natco Pharma USA LLC	69339-364	69339-0364-05
Carboplatin	Carboplatin 150 mg/15mL	Injection, SolutionIntravenous	Natco Pharma USA LLC	69339-365	69339-0365-15
Carboplatin	Carboplatin 450 mg/45mL	Injection, SolutionIntravenous	Natco Pharma USA LLC	69339-366	69339-0366-45
Carboplatin	Carboplatin 600 mg/60mL	Injection, SolutionIntravenous	Natco Pharma USA LLC	69339-367	69339-0367-60
Carboplatin	Carboplatin 600 mg/60mL	Injection, SolutionIntravenous	Teyro Labs Private Limited	82511-006	82511-0006-60
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	BPI Labs LLC	54288-164	54288-0164-01
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	BPI Labs LLC	54288-165	54288-0165-01
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	BPI Labs LLC	54288-166	54288-0166-01
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	BPI Labs LLC	54288-167	54288-0167-01
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-150	61703-0150-05

All 32 Carboplatin NDCs

Other NDCs under ANDA 076517

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076517
Product	Strength	Form · route	Labeler	Product NDC
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-150
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-262
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-360